310 related articles for article (PubMed ID: 17950827)
1. Drug-eluting stent safety.
Slottow TL; Waksman R
Am J Cardiol; 2007 Oct; 100(8B):10M-17M. PubMed ID: 17950827
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting stent thrombosis.
Steinberg DH; Satler LF
Minerva Cardioangiol; 2008 Feb; 56(1):127-37. PubMed ID: 18432175
[TBL] [Abstract][Full Text] [Related]
3. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent.
Zhang F; Qian J; Ge J
J Invasive Cardiol; 2008 Aug; 20(8):423-5. PubMed ID: 18688068
[TBL] [Abstract][Full Text] [Related]
4. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model.
Garg P; Cohen DJ; Gaziano T; Mauri L
J Am Coll Cardiol; 2008 May; 51(19):1844-53. PubMed ID: 18466798
[TBL] [Abstract][Full Text] [Related]
5. Stent thrombosis in the era of drug eluting stents.
Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting stents: issues of late stent thrombosis.
Lemesle G; Maluenda G; Collins SD; Waksman R
Cardiol Clin; 2010 Feb; 28(1):97-105. PubMed ID: 19962052
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
Qasim A; Cosgrave J; Latib A; Colombo A
Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
Ducrocq G; Serebruany V; Tanguay JF
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
[TBL] [Abstract][Full Text] [Related]
9. Safety of drug-eluting stents.
Windecker S; Jüni P
Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):316-28. PubMed ID: 18414453
[TBL] [Abstract][Full Text] [Related]
10. A critical appraisal of the safety and efficacy of drug-eluting stents.
Maluenda G; Lemesle G; Waksman R
Clin Pharmacol Ther; 2009 May; 85(5):474-80. PubMed ID: 19279567
[TBL] [Abstract][Full Text] [Related]
11. The safety of drug-eluting stents.
Saia F; Marzocchi A; Branzi A
Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):43-52. PubMed ID: 19124407
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.
Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Slottow TL; Xue Z; Torguson R; Kaneshige K; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
Am J Cardiol; 2009 Feb; 103(4):496-500. PubMed ID: 19195509
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Rossini R; Musumeci G; Aprile A; Valsecchi O
Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):49-61. PubMed ID: 20121564
[TBL] [Abstract][Full Text] [Related]
14. [Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S; Hoffmeister HM; Bode C
Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
[TBL] [Abstract][Full Text] [Related]
15. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
16. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
[TBL] [Abstract][Full Text] [Related]
19. Off-label use of stents: bare-metal versus drug-eluting stents.
Girod JP; Mulukutla SR; Marroquin OC
Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1095-106. PubMed ID: 18793112
[TBL] [Abstract][Full Text] [Related]
20. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
Kumbhani DJ; Bavry AA; Bhatt DL
Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
